Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy.

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Exon skipping compounds are approved for Duchenne muscular dystrophy (DMD).
• Current research focuses on developing compounds to skip additional exons and improve delivery to skeletal muscle.
• Genome editing is being explored as an alternative to restore the reading frame at the DNA level.

Purpose of the Study:

• To outline developments in reading frame restoring approaches for DMD.
• To discuss challenges in mutation specificity and delivery optimization.
• To highlight efforts in detecting therapeutic effects of exon skipping in clinical trials.

Main Methods:

• Literature search focusing on recent publications (<3 years).
• Review of current advancements in exon skipping and gene editing technologies.
• Analysis of challenges and ongoing efforts in the field.

Main Results:

• Three antisense oligonucleotide (AON) therapies are currently approved for DMD.
• Further confirmation is needed on whether achieved dystrophin levels can slow disease progression.
• Strategies to enhance AON uptake by muscles are under investigation.

Conclusions:

• Gene editing presents an alternative but involves practical and ethical considerations.
• The efficiency of frame-restoring approaches is expected to improve due to field momentum.
• Continued research is crucial for optimizing DMD therapies.